Serum Institute Of India

SII's Covovax Covid Vaccine Now Available For Children In India, Says CEO Adar Poonawalla

NTAGI Approves SII's Covovax Covid-19 Vaccine For Children Between 12-17 Age Group: Report

Covovax First Indian COVID Vaccine To Be Sold In Europe, Says SII's Adar Poonawalla

Covishield, Covaxin Prices Revised For Private Hospitals Day Before Booster Drive Begins — Check Rates

SII's Covovax Gets Emergency Approval For Children Aged 12-17 Years

Serum Institute Seeks EUA For Its Covovax Vaccine For 12-17 Years Age Group

Covishield, Covaxin Granted Regular Market Approval For Use In Adult Population

Prices Of Covishield, Covaxin Likely To Be Capped At Rs 275 After Regular Market Approval

SII Gets DCGI Nod To Manufacture Drug Substance, Test It For Developing Jab Against Omicron

CDSCO Panel Recommends Emergency Use Authorisation For SII's Covid vaccine Covovax

Covovax Covid Vaccine Gets WHO Approval, Adar Poonawalla Calls It 'Another Milestone'

Amid Omicron Fear, Expert Committee Gives No Recommendations For COVID Booster Dose: Report